Abstract
BackgroundThe purpose of the study was to investigate the expression and prognostic value of STAT3 in diffuse large B-cell lymphoma (DLBCL).MethodsSeventy-four DLBCL patients from 2001 to 2007 were reviewed in the study. The STAT3 expression in their tumor tissues was examined using the immunohistochemistry (IHC) method, and evaluated for its association with clinicopathological parameters.ResultsStrong nuclear staining of STAT3 and phosphorylated-STAT3tyr705 (P-STAT3) were observed in 19 cases (25.7%) and 24 cases (32.4%), respectively, and the expression levels were highly consistent between them (P = 0.001). The high nuclear expression of STAT3 was more frequent in the non-germinal center B cell-like (non-GCB) DLBCL than that in the GCB subtype, but not reaching significance (P < 0.061). The high nuclear expression of STAT3 was found to be correlated with poor overall survival (OS) (P = 0.005). Multivariate Cox regression analysis showed that the STAT3 expression was an independent prognostic factor for DLBCL patients regardless of CHOP or R-CHOP regimen used as the first-line therapy.ConclusionSTAT3 is more frequently expressed in non-GCB DLBCL than that in GCB subtype, and its strong nuclear expression is correlated with poor OS in DLBCL.
Highlights
Diffuse large B-cell lymphoma (DLBCL) is defined by the World Health Organization (WHO) Classification as a heterogeneous entity, encompassing morphologic and genetic variants, and variable clinical presentations and outcomes [1]
Molecular subtypes of germinal center B cell-like (GCB) and non-germinal center B cell-like diffuse large B-cell lymphoma (DLBCL) subtypes are proposed to stratify the prognosis of DLBCL in addition to the International Prognostic Index (IPI) score [5,6,7], but the application of Rituximab reduced the prognostic difference between the two subtypes [8,9]
Twenty nine patients were diagnosed with B symptoms, 50 patients had stage III-IV diseases and 50 patients were diagnosed with the non-germinal center B cell-like (non-GCB) subtype
Summary
Diffuse large B-cell lymphoma (DLBCL) is defined by the World Health Organization (WHO) Classification as a heterogeneous entity, encompassing morphologic and genetic variants, and variable clinical presentations and outcomes [1]. It accounts for 80% of aggressive lymphomas [2]. STAT pathway triggers the activity of receptor-associated Janus kinase (JAK) family members and cross-talks with the nuclear factor-B (NF-B) pathway, which is an important molecular pathogenesis of lymphoma [13]. The purpose of the study was to investigate the expression and prognostic value of STAT3 in diffuse large B-cell lymphoma (DLBCL)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call